Health Care · Biological Products, (No Diagnostic Substances)

KYTX Kyverna Therapeutics Inc SEC Filings & Insider Trading Activity 2026

company
CIK 199470248 filings

KYTX at a glance

Kyverna Therapeutics Inc (KYTX, SEC CIK 1994702) filed its latest 10-K annual report on March 26, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and Form 4 insider filings as recently as May 29, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • As of September 30, 2026, 26 institutional investment managers tracked by SignalX reported holding Kyverna Therapeutics Inc (KYTX) shares worth $110.4 million in 13F-HR filings.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
26 funds
$110.4M · +3 vs prior quarter
Latest 8-K
Nov 12, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • New legal risk: securities class action survived dismissal of Sections 11 and 15 claims on October 20, 2026
  • Regulatory risk: FDA CAR-T malignancy investigation could require boxed warnings, lifetime monitoring, or added post-approval obligations
  • Operational risk: miv-cel BLA submitted in fourth quarter 2026, but FDA acceptance and approval remain uncertain
  • Financial risk: $120.0 million nine-month net loss and $544.8 million accumulated deficit require substantial additional capital
  • Competitive risk: miv-cel faces approved therapies including Rituxan and Ocrevus plus emerging CAR-T and T-cell engager treatments

Management Discussion & Analysis

  • Quarterly revenue $0, unchanged YoY, with no approved products or product sales
  • Net loss $41.9M vs $36.8M YoY, operating loss $42.9M vs $38.7M
  • R&D $27.0M, down 11%; G&A $15.9M, up 92%, worst cost trend
  • Cash, equivalents and marketable securities $170.6M; nine-month operating cash use $117.3M
  • SPS BLA completed in fourth quarter 2026, potential 2027 launch; funding expected for at least 12 months

AI summary of the KYTX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 12, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results and business update released for quarter ended September 30, 2026
  • Investors should review Exhibit 99.1 for operating metrics, cash position and pipeline developments

Item EX-99.1: Item EX-99.1

  • BLA submission completed for miv-cel in stiff person syndrome, with FDA priority review requested
  • Potential 2027 launch would target the first approved SPS therapy and autoimmune CAR-T, creating significant commercial upside if approved
Filed Sep 24, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Positive one-year KYSA-8 data for miv-cel in stiff person syndrome, supporting registrational development
  • Positive longer-term Phase 2 KYSA-6 follow-up in generalized myasthenia gravis, strengthening durability evidence

Item EX-99.1: Item EX-99.1

  • SPS 12-month data: 49% median T25FW improvement, with 95% sustaining clinically meaningful benefit
  • 67% of pre-treatment walking-aid users remained independent, supporting meaningful reversal of disability
Filed Aug 11, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Kyverna reported financial results for the quarter ended June 30, 2026
  • Business update and quarterly results available in Exhibit 99.1, relevant for pipeline and liquidity assessment

Item EX-99.1: Item EX-99.1

  • RMAT designation for miv-cel in non-active SPMS expands regulatory pathways and supports a broader neuroimmunology franchise
  • Rolling SPS BLA submission on track for Q4 2026, with potential priority review and 2027 commercial launch

AI summaries of KYTX 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for KYTX

Don't miss the next KYTX filing

  • Alerts as it files. A push when KYTX files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut KYTX, by share count.
  • Ask anything. An AI agent that reads every KYTX filing and answers with sources.

KYTX alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Shaw ChristiFMay 27, 2026$8.59
CLARK IAN TAMay 27, 2026-
SEIDENBERG BETH CAMay 27, 2026-
SEIDENBERG BETH CAMay 27, 2026-
Cohen Fred EAMay 27, 2026-
Cohen Fred EAMay 27, 2026-
Aktar MertAMay 27, 2026-
Aktar MertAMay 27, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Operating Income-$62.4M-$142.6M-$169.8M
Net Income--$127.5M-$161.3M
Balance Sheet
Total Assets$75.2M$304.6M$293.8M
Equity-$131.4M$266.6M$232.3M
ROE--47.8%-69.4%
Per Share
EPS$-89.61$-3.33$-3.64
Cash Flow
Operating CF-$52.4M-$114.3M-$153.7M
CapEx$621K$2.2M$5K

Source: XBRL data in Kyverna Therapeutics Inc (KYTX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate KYTX share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
KYTX shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202626$110.4M
Q2 202623$141.7M
Q1 202623$108.9M
Q4 202521$108.8M
Q3 202521$57.3M
Q2 202521$31.4M
Q1 202519$16.6M
Q4 202415$31.0M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 169 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

KYTX filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 12, 2026Analysis-
10-QNov 12, 2026Analysis
8-KSep 24, 2026Analysis-
10-QAug 11, 2026-
8-KAug 11, 2026Analysis-
8-KJul 27, 2026Analysis-
8-KJul 9, 2026Analysis-
8-KJun 2, 2026-
4May 29, 2026-
4May 29, 2026-
4May 29, 2026-
4May 29, 2026-
4May 29, 2026-
4May 20, 2026-
8-KMay 18, 2026-
8-KMay 12, 2026-
10-QMay 12, 2026-
4May 6, 2026-
8-KMay 4, 2026--
8-KApr 22, 2026--
8-KApr 22, 2026--
8-KApr 20, 2026--
8-KMar 26, 2026--
10-KMar 26, 2026-
4Mar 17, 2026--

Related Health Care companies

All Health Care →

KYTX SEC filings: frequently asked questions

Which institutions hold KYTX stock?

As of September 30, 2026, the largest Kyverna Therapeutics Inc (KYTX) holders among the 13F filers tracked by SignalX were Gilead Sciences ($28.1 million), BlackRock ($22.0 million), Vanguard Capital Management LLC ($13.7 million), T. Rowe Price Group ($8.2 million), State Street Corp ($8.2 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What did KYTX report in its latest 8-K?

Kyverna Therapeutics Inc (KYTX) filed an 8-K on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results and business update released for quarter ended September 30, 2026.

What are the latest KYTX SEC filings?

Kyverna Therapeutics Inc (KYTX) filed its latest 10-K annual report on March 26, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and a Form 4 insider filing on May 29, 2026.

What is KYTX's SEC CIK number?

Kyverna Therapeutics Inc (KYTX)'s SEC Central Index Key (CIK) is 1994702. EDGAR lists every KYTX filing under that number.

Ask anything about KYTX

The research agent reads KYTX's filings, financials, insider trades and 13F holders, then answers with sources.